One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study

ConclusionsUnadjusted 2-year persistence is suboptimal. However, both teriparatide and denosumab users had better 1-year persistence and only denosumab had 2-year better persistence compared to alendronate users. Unmeasured confounding by indication might partially explain our findings.

Source: Osteoporosis International - July 16, 2017 Category: Orthopaedics Source Type: research